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Abstract
Developmental exposure to BPA is associated with liver dysfunction and
diseases in adulthood. However, the effects of BPA on liver development are
unknown. To address this question, pregnant mice were exposed to BPA via diet from
embryonic day 7.5 (E7.5) to E18.5. At E18.5, fetal livers were collected, and
analyzed for changes in the expression of key hepatic maturation markers. We found
the following significant protein alterations in BPA-exposed female but not male fetal
livers: (a) mature hepatocyte markers, albumin and glycogen synthase, were
decreased; (b) immature hepatocyte marker, alpha-fetoprotein, was increased; (c)
master transcription factor of hepatocyte differentiation, C/EBP-α, was downregulated; and (d) PCNA (cell proliferation marker) was elevated, while caspase-3
(marker of apoptosis) was reduced. These findings demonstrate that prenatal exposure
to BPA disrupts molecular maturation of the mouse fetal liver in a sex-specific
manner, and suggest that females are more vulnerable to BPA-induced liver
dysfunction and diseases.
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Chapter 1 – Introduction
1.1 Bisphenol A
Bisphenol A (BPA) is a prominent endocrine-disrupting chemical (EDC) that has
fueled major public health concerns due to its association with a wide range of metabolic,
reproductive, cardiovascular, and neurological disorders as well as cancer [1–3]. It is one
of the highest volume chemicals produced in the world, with over 8 billion pounds being
produced annually [4]. As a building block of polycarbonate plastics, as well as a major
component of epoxy resins [4–6], BPA is used extensively in the manufacture of a
number of consumer goods and products, including reusable food and beverage
containers, dental sealants, polyvinyl chloride stretch films, tin can linings, cardboards,
and papers used in register receipts [1,4,6,7]. Consequently, BPA has also been detected
in water, dust, as well as indoor and outdoor air samples [1,8]. Because BPA is
ubiquitously present in the environment, it can exert its harmful effects through multiple
routes of exposure including ingestion, inhalation, and dermal absorption [1,8]. Humans
are most commonly exposed to BPA via diet [9], as free (active) BPA has a tendency to
leach out of food and beverage containers, routinely entering our food and drinks
[4,6,10].

1.1.1 Pharmacokinetics
Following ingestion, BPA is absorbed from the intestines and transported to the
liver to be metabolized by glucuronidation during first-pass metabolism [11,12].
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Unconjugated BPA is rapidly metabolized into inactive BPA glucuronide (BPA-GA) via
UDP-glucuronyltransferases (UGTs), most notably UGT2B1, as well as into inactive
BPA sulfate metabolites via sulfotransferase (SULT) enzymes [8,13]. BPA metabolism is
similar between humans, non-human primates, and rodents in that the major metabolite
formed is BPA-GA, accompanied by small amounts of BPA sulfate [11]. However, one
species difference exists in terms of BPA elimination. In humans and non-human
primates, BPA is cleared from the blood and excreted via the renal system, whereas in
rodents, BPA conjugates are eliminated primarily in the feces via bile, with only small
amounts excreted in the urine [12]. This species difference in route of clearance has led
some to speculate that levels of BPA clearance must also be vastly different between
humans and rodents. However, Taylor et al. have confirmed that oral administration
results in similar internal exposures to unconjugated BPA in primates and rodents, with a
virtually identical rate of clearance [12]. Other studies have also established that the
pharmacokinetics of BPA are comparable between humans and rodents [12,14], and
regulatory agencies have subsequently deemed rodent models appropriate for assessing
the effects of BPA [14].
It has been previously assumed that following oral ingestion, first-pass
metabolism of BPA is complete with virtually all ingested BPA being conjugated in the
liver [15], attenuating the need for concern in regards to potential health effects
underlying BPA exposure. However, this assumption surfaced mainly from the findings
of one single study that failed to detect unconjugated BPA in human plasma and urine
samples [12]. Importantly, this study was characterized by fundamental design flaws
including a limited sample size as well as the use of a relatively insensitive assay [15].
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More recent findings from pharmacokinetic studies using both mice [16] and
primates [12] have demonstrated that first-pass metabolism is in fact incomplete. Results
from several biomonitoring studies in humans also indicate internal BPA exposure, given
that measurable concentrations of unconjugated BPA are detected in urine [17], which
suggests the following: (a) first-pass metabolism is not complete; (b) a portion of BPA
entering the body circumvents first-pass metabolism; and/or (c) BPA metabolites are
being deconjugated in the body [14,17]. Indeed, studies using rodents have found that a
portion of conjugated BPA undergoes deconjugation via enzymes in the intestine and
colon [8]. Glucuronidase enzymes are also apparent in the digestive tracts of humans,
especially those of infants, likely indicating their ability to deconjugate and re-activate
conjugated BPA [8].
The relative bioavailability of BPA is largely dependent upon route of
administration. While orally administered BPA is subject to first-pass metabolism, BPA
administered via other routes will bypass this process, leading to higher concentrations of
active BPA in circulation [14]. For instance, compared to oral administration, systemic
blood concentrations of BPA are markedly higher following subcutaneous or
intraperitoneal injection, which indicates higher bioavailability [18]. These findings
provide a likely explanation for why the relative potency of BPA is also dependent on
exposure route. For example, subcutaneous BPA administration tends to yield effects at
much lower doses compared to other routes of exposure [15].
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1.1.2 Mechanisms of Action
According to the US Environmental Protection Agency (EPA), an EDC is defined
as “an exogenous agent that interferes with the production, release, transport,
metabolism, binding, action, or elimination of natural hormones in the body responsible
for the maintenance of homeostasis and the regulation of developmental processes” [7].
BPA is most commonly referred to an estrogenic EDC because of its ability to disrupt the
activity of endogenous estrogens [7]. Estrogens are a group of steroid hormones derived
from cholesterol [1], and are critically involved in regulating the growth, differentiation,
and function of a number of different target tissues [19]. While estrogens diffuse in and
out of all cells, they are retained with high affinity and specificity in target cells via
interaction with the estrogen receptor (ER) [1]. The ER is located mainly in the cell
nucleus where, once bound by an estrogen, it will undergo a conformational change and
bind to response elements in the promoter region of certain estrogen target genes [19,20].
As a result, coregulatory proteins (coactivators or corepressors) are recruited to the
promoter region of the target gene, leading to a respective increase or decrease in mRNA
levels and associated protein production [21]. ER can also act via non-genomic
mechanisms, as outlined by Deroo et al. [21]. In mammals, the two major ER subtypes
are ERα and ERβ. These subtypes are encoded by separate genes (ESR1 and ESR2,
respectively), and exhibit distinct tissue-specific expression patterns [21]. In tissues
where they are coexpressed, ERα and ERβ can sometimes exert differential effects, and
can also influence the actions of one another [22].
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It is well established that upon binding to nuclear ER, BPA can induce estrogenic
signals that modify estrogen-responsive gene expression [7]. BPA can bind to both ERα
and ERβ, with a ten times higher affinity for ERβ [2]. Specifically, BPA has been shown
to act as an agonist for ERβ, while demonstrating dual effects as an agonist and
antagonist in some cell types via ERα [23]. Hence, the activity of BPA is largely
dependent on ER subtype and cell type, which can be partially attributed to the
differential effect of BPA on the recruitment of coactivator proteins by ERα and ERβ
[7,24].
BPA has been classified as a weak estrogen based on its low binding affinity for
ER compared to naturally-occurring 17β-estradiol (~10,000-fold lower) [14,25].
Previously, this has led to the notion that BPA might be unable to create an impact in the
midst of the already strong effects of endogenous estrogens. However, Rajapakse et al.
demonstrate that the combination effect of estradiol and BPA is in fact additive [26]. The
spare receptor hypothesis describes how typically, a maximal biological response can be
achieved by low concentrations of a hormone, well before receptor occupancy becomes
saturated [14]. The presence of these “spare receptors” provides a mechanism for why
low doses of an EDC such as BPA might exert a response, regardless of its low affinity
for the receptor [25]. In addition, BPA has been shown to interact with ER in a nonclassical manner that is distinct from other known groups of ER ligands [25,27], leading
to the induction of a unique subset of ER-responsive genes and associated physiological
responses [28]. Moreover, while BPA is less potent than estradiol upon binding to
nuclear ER, its potency is evidenced to be just as high as that of estradiol when its action
is mediated by ERs outside the nucleus [7].
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Importantly, the endocrine disrupting actions of BPA extend beyond its ability to
modulate the activity of endogenous estrogens. More recently, it has become apparent
that BPA can bind to the androgen receptor (AR) and thyroid receptor (TR) as an
antagonist [29]. In addition, BPA can bind to the glucocorticoid receptor (GR) as both an
agonist and antagonist [30,31], and has also been shown to possess strong binding
affinity for the estrogen-related receptor γ (ERRγ) [32]. In addition, BPA can act via
variety of intracellular signal transduction pathways directly via mechanisms independent
of nuclear hormone transactivation [7,8]. Certain metabolites of BPA have even been
suggested to be more potent than the parent compound itself [33].

1.1.3 Dose-Response and Low-Dose Effects
Typically, regulatory testing of a chemical involves the establishment of a lowest
observed adverse effect level (LOAEL), which is the lowest dose at which an adverse
effect is observable, and/or a no observed adverse effect level (NOAEL), defined as the
highest exposure level at which no observable adverse effects are present [14]. After a
series of calculations, a reference dose is then produced which becomes the allowable
exposure level that is deemed safe for humans [14]. This standard procedure was based
on one of the traditional notions in toxicology being that “the dose makes the poison”.
This idea implies that the larger the dose of a chemical substance, the greater the
physiological response. However, studies of EDCs have challenged this concept,
including those of BPA, demonstrating that low-dose effects exist which cannot be
predicted by the effects observed at high doses [14]. This is due to the fact that BPA and
other EDCs often exhibit non-monotonic versus monotonic dose-response relationships
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[34]. Monotonic dose response curves can be linear or non-linear, but the sign of the
slope remains constant. In contrast, non-monotonic dose response curves (NMDRCs)
present as U-shaped or inverted U-shaped curves, with the sign of the slope changing
from positive to negative (or vice-versa) at some point of along the range of examined
doses [14]. In other words, BPA’s action (or lack thereof) at low doses cannot simply be
inferred by the presence or absence of an effect of BPA at a higher dose [34,35]. Thus,
the traditional approach of using high-dose testing regimens to assess chemical safety at
low doses is particularly problematic for EDCs.
This issue reinforces the importance of environmentally relevant doses in studies
examining the effect of an EDC. In animal models, an administered dose of a chemical
that creates internal concentrations within the range of what has been measured in the
general human population is considered “environmentally relevant” [14].
Environmentally relevant doses are considered “low doses”, and the biological effects
that arise from environmentally relevant doses are often referred to as “low-dose effects”.
Importantly, epidemiological studies have repeatedly linked low doses of BPA to adverse
health and increased disease prevalence in the general population [14].

1.2 BPA During Pregnancy
EDCs can elicit different effects depending on the life stage during which an
animal is exposed [36]. After puberty, exposure to EDCs results mainly in “activational
effects”, which are transient and generally reversible. Conversely, during critical periods
of development, EDCs may exert permanent “organizational effects” that persist even in
the absence of subsequent exposure [36]. Exposure to BPA during pregnancy is of
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particular concern, as fetal organs are undergoing critical developmental processes.
Previous studies indicate that BPA reaches the fetus during pregnancy, and exposure to
BPA in utero has been shown to alter the development of several fetal organs, including
the brain [37,38], heart [39], mammary glands [40–42], ovaries [43,44], uterus [45],
testes [46], and lungs [47].

1.2.1 Developmental Origins of Health and Disease
The Developmental Origins of Health and Disease (DOHaD) concept describes
how early life environmental perturbations can exert programming effects on the fetus,
leading to permanent changes in the body’s structure, function, and metabolism, and
increasing the risk for disease later in life [48]. This hypothesis was first proposed by
David Barker in the 1980’s, who revealed that the starvation of Dutch pregnant women
during World War I was correlated with an increased risk for adult-onset of
cardiovascular and metabolic disease in their underweight offspring [49]. This
association was subsequently confirmed in a number of worldwide longitudinal studies
[50], and undernutrition during gestation was considered an important early fetal origin
of cardiovascular and metabolic disorders [48]. As the DOHaD gradually gained
acceptance, the focus of research expanded to incorporate a number of other factors
during gestation that might exert programming effects on the fetus [51].
It has now become clear that many diseases have their origins during fetal
development [51]. The prenatal period is considered especially critical given the
increased sensitivity of tissues undergoing growth, differentiation, and physiological
maturation [49]. Accordingly, the fetus is especially vulnerable to the adverse effects of
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EDCs, such as BPA. Environmental influences do not usually result in significant defects
or malformations that are apparent at birth, but rather manifest as subtle functional
changes (increased cell numbers, altered gene expression, etc.) that increase the risk for
dysfunction and diseases later in life [49]. Sex-specific effects may also apparent as early
as in the developing fetus [49].

1.2.2 Fetal Exposure to BPA
One of the major functions of the placenta is to act as a barrier for the fetus
against xenobiotics such as drugs and other compounds [52]. However, the placenta
seems to serve as a rather ineffective barrier against BPA. Due to its high lipid-solubility,
free BPA can rapidly cross the placenta in both directions, mainly via passive diffusion
[53,54]. Although the placenta expresses UGTs and SULTs, studies have shown that only
negligible amounts of BPA are conjugated by the placenta [54]. Moreover, BPA has been
detected in maternal blood, umbilical cord blood, fetal blood, placental tissue, and
amniotic fluid [52,54–56], suggesting that BPA reaches the fetus during pregnancy.
During fetal development, endogenous estrogens are predominantly bound to
alpha-fetoprotein (AFP), a high affinity binding protein produced by the fetal liver
[14,57]. Accordingly, the developing fetus is protected from excessive estrogen exposure,
as relatively low levels of endogenous estrogens circulate as the free, biologically active
form [57]. Conversely, BPA possesses a limited binding capacity for AFP [57]. Thus,
although BPA possesses a lower affinity for ER compared to estradiol, its estrogenic
effects in utero are suggested to be greater than would be expected, given that a higher
proportion of BPA circulates as the free, biologically active form [57].
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Moreover, the Oatp and Mrp family of transporters have been implicated in the
maternal-fetal transport of BPA-GA, the concentration of which is reportedly elevated in
maternal blood of pregnant women for the entire gestational period [3]. Specifically,
studies have shown that BPA-GA is carried from maternal blood vessels to trophoblast
cells by the Oatp4a1 (influx) transporter, and then transported to fetal cells from
trophoblasts via the Mrp1 (efflux) transporter [52]. Since these metabolites are watersoluble, they are less able to cross the placenta and once excreted in fetal urine, are
trapped in amniotic fluid with the potential to be swallowed and re-circulated in the fetus
[53]. Although BPA-GA is an inactive metabolite, fetal tissues possess the ability to
deconjugate BPA-GA to active BPA via the enzyme β-glucuronidase [52]. The majority
of deconjugation occurs in the fetal liver [52], which also represents the major site of
BPA accumulation [58]. Deconjugation is also evident in the heart, but to a much smaller
degree [52]. This, in combination with the limited drug metabolizing system of the fetus
[52,55], further exacerbates fetal exposure to BPA.

1.3 The Liver
The liver is the largest internal organ, accounting for 2-5% of total body mass
[59], and is responsible for carrying out a number of exocrine, endocrine, and metabolic
functions [60,61] that are essential for the maintenance of overall homeostasis [62,63].
Structurally, the liver is characterized by a complex tissue architecture that is critical for
normal hepatic function [59]. The liver also possesses the remarkable capacity to
completely regenerate when up to 70% of its volume is removed [60].
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1.3.1 Physiological Functions
Hepatocytes are major functional cells of the liver and account for approximately
80% of total liver volume. One of the key functions of hepatocytes is the production of
proteins, including albumin (25% of hepatic protein production), lipoproteins, globulins,
clotting factors, and certain hormones [64]. Hepatocytes also produce bile for the purpose
of aiding in the absorption of fats as well as the excretion of other water-insoluble
substances [64]. Subsequent to its production in the liver, bile is transported to the gall
bladder for storage until being released into the small intestine during a meal. One of the
most critical functions of the liver is the regulation of blood glucose levels. The liver is
the major site of gluconeogenesis [64]. Additionally, hepatocytes will store excess
glucose as glycogen after a meal, where its synthesis and degradation is hormonally
regulated to maintain whole-body blood glucose requirements [64,65]. The liver is also
essential for the metabolism of other dietary compounds, as well as detoxification, urea
metabolism, and cholesterol synthesis and transport [59,60].
The remaining 20% of the liver is made up of a diverse group of non-parenchymal
cells that function in concert with hepatocytes, including biliary epithelial cells (BECs;
also known as cholangiocytes), endothelial cells, Kupffer cells (macrophages), stellate
cells, and pit cells (natural killer cells) [59]. Table 1-1 summarizes each cell type and
their respective functions.

12

Cell Type

Population (%)

Position

Function(s)
- Protein production &
secretion
- Bile production & secretion
- Glucose metabolism

Hepatocyte

~80%

Parenchyma

- Glycogen metabolism &
storage
- Detoxification
- Cholesterol metabolism
- Urea metabolism
- Bile transport

~3%

Cholangiocyte

Bile duct
epithelium

Vasculature

- Water & bicarbonate
secretion
- Form walls of veins, arteries,
venules, arterioles

Endothelial
cells

~3%

Kupffer cells

~2%

Sinusoids

- Specialized Macrophages

Stellate cells

~1.5%

Perisinusoidal

- Vitamin A & retinoid storage

Pit cells

rare

Sinusoidal
lumen

- Cytotoxic activity

- Control blood flow

Table 1-1. Adult Liver Cell Types and Respective Functions. Hepatocytes are the
major functional cells of the liver and account for approximately 80% of total liver
volume. The rest of the liver is made up of a diverse group of cell types that function in
concert with hepatocytes.
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1.3.2 Cellular Architecture
The intrahepatic bile duct (IHBD), portal vein, and hepatic artery run in parallel
within the liver, and are collectively referred to as the portal triad [60] (Figure 1-1). Each
portal triad marks roughly one of six corners of the liver lobule, the basic architectural
unit of the liver, which consists of single sheets of hepatocytes (hepatic plates) lined by
sinusoidal capillaries [59] (Figure 1-1). The lobule is supplied with blood by the portal
vein and hepatic artery which, after flowing through the sinusoidal capillaries, exits the
lobule via the central vein [59] (Figure 1-1). The portal vein sends blood directly to the
basal surface of hepatocytes, where the absorption of metabolites and toxins occurs [60].
Hepatocytes are adjoined via tight junctions that form a canaliculus, which receives bile
secreted from the apical surface. Bile is then carried through the IHBDs and extrahepatic
bile ducts (EHBDs) to the gall bladder for storage [59,60].
The smallest functional unit of the liver is the hepatic acinus, which is positioned
between two portal triads, and extends outwards in both directions towards the central
veins [66] (Figure 1-1). The acinus is divided into three separate zones that each consist
of hepatocytes specialized for slightly different functions. Zone 1 is defined according to
its proximity to the portal triad. These hepatocytes are exposed to blood with the highest
nutrient and oxygen concentrations, and consequently perform the majority of the liver’s
metabolic functions (glycogenesis, gluconeogenesis, lipid metabolism, and protein
synthesis) [66]. Hepatocytes in Zone 3 are positioned closest to the central vein, and are
responsible for carrying out glycolysis, urea synthesis, and biotransformation reactions
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[66]. Lastly, the functions of hepatocytes in Zone 2 depend mainly on their relative
proximity to Zones 1 and 3.

15

Figure 1-1. Simplified Schematic Diagram of Hepatic Cellular Architecture. The
IHBD, portal vein, and hepatic artery make up the portal triad, which marks roughly one
of six corners of the liver lobule. Each lobule consists of a central vein from which
hepatic plates radiate out. Sinusoidal capillaries are located in between plates of
hepatocytes (not shown). The hepatic acinus is positioned between two portal triads, and
extends outwards in both directions towards the central veins.

16

1.3.3 Sexual Dimorphism
The liver is known to exhibit a considerable degree of sexual dimorphism. For
example, metabolic function of the liver is known to be markedly sexually dimorphic,
which mainly reflects underlying sex differences in the hepatic expression of enzymes
such as cytochromes P450, UDP-glucuronosyltransferases, and sulfotransferases [67].
Such enzymes are essential for the metabolism of drugs, fatty acids, environmental
toxins, and steroids [67]. Accordingly, the prevalence of a variety of diseases tends to
differ between males and females [68]. These patterns are largely mediated by sexspecific secretions in endogenous hormones such as androgens, estrogens, and growth
hormone [69].
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1.4 Fetal Liver Development
During early gestation, the fetal liver functions largely as a hematopoietic organ
[70]. By embryonic day (E) 12.5, the fetal liver is considered the primary site of
hematopoiesis [70], with a peak in hematopoietic activity apparent at E13.5 [71]. By
E16.5, the major site of hematopoiesis switches to the bone marrow and spleen, at which
point the liver begins to acquire its metabolic phenotype [71].

1.4.1 Hepatic Specification and Liver Bud Formation
In the mouse, liver development begins after formation of the definitive gut
endoderm at around E8.5 [72,73]. This corresponds to approximately 3 weeks of
gestation in the human [61]. The foregut endoderm receives signals from the cardiac
mesoderm, septum transversum mesenchyme (STM), and neighbouring endothelial cells
that are necessary for hepatic specification [72,74] and subsequent formation of the liver
bud [72,75]. Additionally, commitment of the ventral endoderm to a hepatic fate and
subsequent liver bud morphogenesis involve the establishment of an essential, complex
network of transcription factors [59].
The developing embryonic liver first appears as the hepatic diverticulum (E8.5 to
E9), a thickened outward extension of the ventral epithelium which is lined by a
basement membrane of endothelial cells [60]. Newly specified pre-hepatic cells are called
hepatoblasts, bipotential and proliferative hepatic progenitor cells that are capable of
giving rise to either hepatocytes or cholangiocytes [61]. Hepatoblasts in the liver bud
already begin to express serum protein genes specific to hepatocytes [75]. Following

18

hepatic specification, the surrounding basement membrane is lost (E9.5) and hepatoblasts
migrate as cords to invade the surrounding STM, forming the liver bud [72]. During this
time, considerable liver growth is apparent due to rapid proliferation of hepatoblasts as
well as increased hematopoietic activity. The STM and hepatic mesenchyme secrete a
variety of growth factors that are important for hepatoblast proliferation and migration
[60]. In addition, signals that prevent apoptosis and promote cell survival further support
liver bud expansion and differentiation [76].

1.4.2 Differentiation of Hepatic Progenitor Cells
Differentiation of bipotential hepatoblasts is initiated at around E13 to E14.5
[60,61,71]. The number of bipotential hepatoblasts gradually reduces as they eventually
become unipotent and irreversibly committed to either the hepatocyte or cholangiocyte
cell lineage. The majority of parenchymal hepatoblasts will differentiate into hepatocytes,
while those residing next to portal veins will become cholangiocytes, which form the
luminal epithelium of IHBDs [61]. The correct overall balance between these two cell
types is achieved by integrated signaling and transcriptional pathways [75] which act to
either induce or repress mechanisms that direct the cell fate of hepatic progenitors [73].
The status of differentiating hepatic progenitor cells can be generally determined with the
use of the following respective cell markers: (1) bipotential hepatoblasts express AFP,
albumin, and cytokeratin (CK)-19; (2) hepatocytes express AFP and albumin, but not
CK-19; and (3) BECs express CK-19, but neither albumin nor AFP [77,78] (Figure 1-2).
Following differentiation into hepatocytes and cholangiocytes, both cell types will
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undergo proliferation to achieve proper liver size [79]. Apoptosis (programmed cell
death) is also essential for shaping the liver and controlling overall cell population [80].
Hepatoblasts initially express genes associated with BECs as well as fetal and
adult hepatocytes (Figure 1-2). Differentiation into cholangiocytes is initiated by signals
from the portal mesenchyme (Wnt, TGFβ) to which adjacent hepatoblasts respond, which
act to promote BEC-specific transcription factors (OC1, OC2, HNF1β) and suppress
hepatogenic transcription factors (HNF4, C/EBP). This results in an upregulation of CK,
and a decrease in the expression of genes specific to hepatocytes [60] (Figure 1-2). Other
factors continue to be secreted by the portal mesenchyme for successful bile duct
formation to proceed (Jagged/Notch, EGF, HGF) [60]. During transformation into
cholangiocytes, periportal hepatoblasts form a monolayer, then a bilayer of BEC cuboidal
precursors, and by E17 and into the perinatal period, the portal mesenchyme begins to
surround focal points depicted in the bilayer of biliary precursor cells, while the
remaining bilayer cells regress [60].
Conversely, hepatoblasts in the parenchyma do not receive signals from the portal
mesenchyme, which causes them to downregulate BEC-associated gene expression,
while allowing them to maintain the expression of genes specific to hepatocytes [60]
(Figure 1-2). By E17, hepatocytes will acquire their characteristic morphology [60],
while functional maturation will resume until after birth.
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Figure 1-2. Differentiation Markers of Hepatic Progenitor Cells. Bipotential
hepatoblasts initially express genes associated with BECs as well as fetal and adult
hepatocytes. Hepatic progenitor cells differentiating into cholangiocytes will upregulate
genes associated with BECs, while downregulating hepatocyte-specific
specific genes.
genes In
contrast, hepatic progenitor cells differentiating into hepatocytes will downregulate BECBEC
associated gene expression, while upregulating hepatocyte-specific
specific genes.
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1.4.3 Functional Maturation of Hepatocytes
Subsequent to lineage segregation and commitment, immature/transitional
hepatocytes gradually differentiate into mature hepatocytes, exhibiting progressive
functional changes up until several weeks after birth. One major functional transition that
takes place is in the production of hepatic plasma proteins. Albumin is the major plasma
protein produced by mature hepatocytes, constituting more than half of total plasma
protein concentration in the adult [81]. Albumin synthesis takes place exclusively in the
liver, and is secreted into circulation as soon as it is manufactured [81] where it becomes
involved in the binding and transport of various drugs, hormones, lipids, and anions, and
the maintenance of oncotic pressure [82]. Albumin mRNA is first detected in fetal
hepatocytes at E10.5 (gestational week 16 in humans), and its expression increases
progressively thereafter until it reaches maximal levels in the adult (Figure 1-3)
[71,83,84].
On the contrary, AFP is the predominant plasma protein produced by the fetal
liver, and is largely considered the fetal equivalent of the adult serum albumin [85].
During prenatal development, AFP expression increases steadily from E9 up to E15.5
(~1000-fold), at which time it begins to decline as the liver matures, ultimately becoming
undetectable in the adult (Figure 1-3) [71,85,86]. This pattern also corresponds to that
observed in humans, where AFP production reaches a peak at the end of the first
trimester and declines thereafter [66]. Because of the respective temporal expression
profiles of albumin and AFP, these two proteins can be effectively used as markers to
determine the status of hepatocyte differentiation if delayed or disrupted maturation is

22

suspected [71]. In particular, albumin is considered a hallmark of mature hepatocytes
[60,87,88], while AFP is commonly used as a marker of immature, fetal hepatocytes
[89,90].
Another important functional transition is in glycogen storage capability. During
most of gestation, hepatic glycogen stores remains low as the fetus obtains an adequate
supply of glucose from the mother via the placenta [66,91]. During late gestation (E17.5),
hepatocytes start to accumulate significant amounts of glycogen in order to prepare for
the extrauterine survival at birth, before the onset of hepatic gluconeogenesis (Figure 13) [92]. In humans, fetal hepatic glycogen stores measure to 3.4 mg/g of liver tissue at 8
to 9 weeks of gestation, and increase to an average of 50 mg/g immediately prior to term
[66,79], amounting to 2-3 times those of adults [79]. This surge in glycogen accumulation
at the end of gestation is accompanied by a corresponding increase in glycogen synthase
[93], the rate-limiting enzyme of glycogen synthesis [94,95]. Thus, glycogen storage is
also used as a marker of mature hepatocytes [88,96,97].
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Figure 1-3. Expression Profiles of Hepatocyte Maturation Markers. Albumin
expression begins in the fetal liver at E10.5, and steadily increases until reaching
maximal levels in the adult. Hepatic glycogen stores remain low until late gestation, at
which point hepatocytes accumulate significant amounts of glycogen such that by term,
glycogen storage amounts to 2-3 times that observed in the adult. Albumin and glycogen
are thus considered hepatocyte maturation markers. In contrast, AFP expression increases
steadily from E9 up until E15.5, at which time it begins to progressively decline as the
liver undergoes continued maturation. AFP is thus considered a marker of immature, fetal
hepatocytes.
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1.4.4 Transcriptional Regulation
Hepatocyte differentiation is associated with alterations in the coordinated
expression of a number of hepatic genes. These genes are primarily controlled through
interactions between several “liver-enriched” transcription factors [98] that are
indispensible for the induction and progression of liver development. These include
hepatocyte nuclear factors (HNFs) HNF-1, HNF-3, HNF-4, HNF-6, and
CCAAT/enhance binding proteins (C/EBPs) [86,98], each of which exhibit their own
temporal expression profiles that coincide with distinct stages of hepatic maturation.
Quantitative gene expression profiling has revealed that HNF-1, HNF-3, HNF-4, and
HNF-6 exhibit particularly similar timelines of expression, with a peak in gene
expression apparent at E9.5 and E11.5 [86]. Based on their expression patterns, these
transcription factors have been suggested to exert primary roles during the earlier phases
of liver development [86]. By contrast, C/EBPs have been implicated during later stages
of development, at which time hepatocytes are undergoing functional maturation.
Correspondingly, expression levels of C/EBP-α and C/EBP-β are most marked in adult
liver tissue [86].

1.4.5 C/EBP-α
As a member of the bZIP class of leucine zipper transcription factors, C/EBP-α
comprises a C-terminal leucine zipper, a basic DNA binding region, and an N-terminal
transactivating region [99], and binds DNA in a sequence-specific manner [100].
Expression of C/EBP-α is tissue-specific, with most abundant levels apparent in liver,
lung, and fat tissue [101]. While targeted disruption of the C/EBP-β gene fails to produce
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substantial consequences on normal liver development [102], a strong mount of evidence
supports a critical role for C/EBP-α in hepatocyte maturation, and its involvement in
regulating the balance between hepatocyte growth and differentiation. In fact, inadequate
maturation of hepatocytes has been attributed specifically to the loss of C/EBP-α [103].
C/EBP-α has been shown to govern the transcription of several hepatocytespecific genes including albumin, AFP, and glycogen synthase [104,105]. Additionally,
C/EBP-α possesses a dominant anti-proliferative effect, and accordingly, its expression is
generally restricted to growth-arrested cells [100]. In fetal hepatocytes, C/EBP-α is
expressed at around E14.5, which corresponds to the time hepatocytes begin to undergo
maturation. Expression of C/EBP-α gradually increases as development proceeds,
reaching a maximum in the adult [102]. The developmental increase in C/EBP-α
expression corresponds to the expression profile of genes associated with mature
hepatocytes, including albumin and glycogen synthase, and is inversely associated with
the expression of the immature hepatocyte marker, AFP. Moreover, neonatal livers of
C/EBP-α knockout mice exhibit properties characteristic of a dedifferentiated state,
including decreased albumin expression, diminished glycogen stores and glycogen
synthase expression, significantly elevated AFP levels, as well as increased cell
proliferation [106,107].
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1.5 Rationale, Objectives, and Hypothesis
1.5.1 Rationale
BPA is one of the most prevalent EDCs in the environment. Of particular concern
is exposure to BPA during pregnancy, a critical time during which key organs are
undergoing growth and differentiation. Previously, exposure to BPA in utero has been
shown to alter the development of several fetal organs, including the brain [37,38], heart
[39], mammary glands [40–42], ovaries [43,44], uterus [45], testes [46], and lungs [47].
The altered fetal organ development following BPA exposure may provide a fetal origin
for various BPA-induced diseases in adult life.
The liver is a key metabolic organ and is essential for the maintenance of overall
homeostasis. Proper liver maturation is critical not only for neonatal survival by
supplying adequate glucose from hepatic glycogen storage, but also for proper hepatic
function later in life [89]. Developmental exposure to BPA is known to be associated
with liver dysfunction and diseases, such as hepatic steatosis [108,109], liver tumors
[110], metabolic syndrome [111,112], and altered hepatic gene expression [113,114] and
DNA methylation profiles [115,116]. However, it is unknown whether these BPAinduced hepatic dysfunctions and diseases have a fetal origin. Therefore, the present
study was designed to address this important question by examining the effects of
prenatal exposure to BPA on fetal liver maturation using the mouse as an experimental
model.
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1.5.2 Objectives
(1) To determine the effects of BPA on overall fetal growth morphology (i.e., fetal
body weight, litter size and sex ratios)
(2) To examine the effects of BPA on fetal liver structural maturation.
(3) To determine the effects of BPA on fetal liver biochemical maturation.
(4) To determine the effects of BPA on the balance between cell proliferation and
apoptosis in the fetal liver.
(5) To ascertain if the effects of BPA on fetal liver maturation are sex-specific.
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1.5.3 Hypothesis
We hypothesize that prenatal exposure to BPA disrupts fetal liver maturation in
the mouse.
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Chapter 2 – Methodology
2.1 Animal Experiments
Breeding pairs of adult C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA). Mice were housed under standard conditions and
provided with food and water ad libitum. Polystyrene cages were utilized in order to
minimize background exposure to BPA beyond treatment regimen. Mice were
maintained at humidity- and temperature-controlled rooms under a normal 12h/12h lightdark cycle. For experiments, 6-8 week old female mice were placed overnight with
males, and pregnancy was determined the next morning by the observation of a vaginal
plug. Plugged females were separated from males, and gestational days were counted,
with presence of a vaginal plug indicating embryonic day 0.5 (E0.5). Pregnant mice were
randomly assigned to receive one of the following two diets: (1) control diet
(phytoestrogen free food pellets supplemented with 7% corn oil; TD.120176, Harlan
Teklad, Madison, WI), or (2) control diet supplemented with 25 mg BPA/kg diet
(TD.120466, Harlan Teklad) (Figure 2-1). Oral administration was chosen to mimic the
most common route of exposure in humans. Feeding was initiated at E7.5, subsequent to
successful implantation and just prior to the onset of liver development, and resumed up
until E18.5 (Figure 2-1). At E18.5, animals were euthanized by CO2 euthanasia (Figure
2-1). Fetuses were recovered by caesarean section, and their weights recorded. In
addition, maternal weight, pup number, and the number of reabsorption sites per uterine
horn were noted. Fetal livers were collected and either snap frozen in liquid nitrogen and
stored at -80°C, or fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer. Fetal
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limbs were also collected, snap frozen in liquid nitrogen, and stored at -80°C.

2.2 Genotyping PCR
Fetal sex was determined by standard polymerase chain reaction (PCR) for the
presence of the male-specific SRY gene. Briefly, DNA was isolated from fetal limb
samples. The PCR reactions were carried out using the Platinum Taq DNA Polymerase
Kit (cat. no. 10966-026, Invitrogen), with the primers SRY-F (5’-GCA GGT GGA AAA
GCC TTA CA-3’) and SRY-R (5’-AAG CTT TGC TGG TTT TTG G-3’). PCR
amplifications were carried out for 30 cycles (20 seconds at 95°C, 20 seconds at 55°C,
and 35 seconds at 72°C) on the Eppendorf Mastercycler® Gradient PCR System
(Eppendorf). PCR products were run on a 1% agarose gel, and fetal sex was determined
to be male if a DNA product at 271-bp (indicative of the presence of the SRY gene) was
observed.

2.3 Histology
Fetal livers were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer
solution (PBS) buffer, dehydrated, and embedded in paraffin wax. Using a rocking
microtome, the lungs were sectioned; 5-µm sections were transferred to Superfrost Plus
microscope slides (Fisher Scientific, Whitby, ON). Sections were stained using a standard
hematoxylin and eosin (H&E) protocol [117].

2.4 Protein Extraction and Western Blot Analysis
Western blot analysis was conducted in order to assess protein expression levels, as
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described previously [117]. Since limited tissue was available to us, we made the
decision to detect protein levels instead of mRNA. Proteins dictate cellular function
[118], and a change in mRNA does not necessarily indicate an alteration in protein
expression levels [119]. Given that the purpose of this study was not mechanistic, but
rather to examine the biochemical maturation of BPA-exposed fetal livers, protein levels
were more meaningful and physiologically-relevant to the present study.
First, liver tissues were homogenized in 10 volumes of ice-cold 10 mM sodium
phosphate buffer, pH 7.0, containing 0.25 M sucrose. Equal volumes of the homogenates
were mixed with SDS gel loading buffer (50 mM Tris·HCl, pH 6.8, 2% wt/vol SDS, 10%
vol/vol glycerol, 100 mM DTT, and 0.1% wt/vol bromophenol blue). Equal
concentrations of this mixture were then subjected to a 10% SDS-PAGE. After
electrophoresis, proteins were transferred to PVDF membranes (Amersham Hybond-P,
cat. no. RPN303F, GE Healthcare Lifesciences, Baie D'Urfe, QC) using a Bio-Rad Mini
Transfer Apparatus. Nonspecific antibody binding was blocked with 5% wt/vol milk in
TBST (0.1% vol/vol Tween-20 in TBS) for 1 hour at room temperature. Membranes were
then hybridized with primary antibody (albumin: cat. no. SAB2100098, 1:5,000 dilution,
Sigma-Aldrich, Saint Louis, MO; glycogen synthase: cat. no. 3886, 1:1,000 dilution, Cell
Signaling Technology, Beverly, MA; AFP: cat. no. sc-8108, 1:1000 dilution, Santa Cruz
Biotechnology, Dallas, TX; C/EBP-α: cat no. sc-61, 1:500 dilution, Santa Cruz
Biotechnology; PCNA: cat. no. 2586, 1:1,000 dilution, Cell Signaling Technology;
caspase-3: cat. no. 9662, 1:1,000 dilution, Cell Signaling Technology; GAPDH: cat. no.
IMG-3073, 1:5,000, Imgenex) overnight at 4°C. The membrane underwent 3 × 10 min
washes with TBST, and was then incubated with an anti-rabbit secondary antibody (cat.
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no. HAF008, 1:500 dilution, R & D Systems) or anti-mouse secondary antibody (cat. no.
G-202-C, 1:10,000 dilution, Fisher Scientific) for 1 hour at room temperature. Following
another 3 x 10 min washes in TBST, proteins were detected using chemiluminescence
(cat. no. WBLUR0500, Luminata Crescendo, Western HRP Substrate; Millipore,
Etobicoke, ON). The membrane was viewed using the VersaDoc Imaging System
(BioRad, UK). Densitometry was performed on the images and the level of various
proteins expressed as percent of controls.

2.5 Statistical Analysis
Results are presented as the mean ± SEM of four different litters. Livers from
three pups were pooled per litter. Data were analyzed using Student’s t-test. Significance
was set at P < 0.05.
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Figure 2-1. Experimental Design. Pregnant mice were randomly assigned to receive one
of the following two diets: (1) control diet (phytoestrogen-free food pellets supplemented
with 7% corn oil); or (2) treatment diet (control diet supplemented with 25 mg BPA/kg
diet). Feeding was initiated at E7.5, subsequent to successful implantation and just prior
to the onset of liver development, and resumed up until E18.5. At E18.5, animals were
euthanized by CO2 euthanasia. Fetal livers were collected and either snap frozen in liquid
nitrogen and stored at -80°C, or fixed in 4% PFA in 0.1 M PBS.
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Chapter 3 – Results
3.1 Effects of BPA on Fetal Body Weight, Litter Size, and
Sex Ratio
As a first step in determining the effect of prenatal exposure on fetal organ
maturation, we examined fetal body weight, litter size, and litter sex ratio at E18.5. We
found that there was no difference in fetal body weight, litter size, or sex ratio (expressed
as percentage of females per litter) between control and BPA-exposed fetuses (Figure 31 A-C).
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Figure 3-1.. Effects of BPA on Fetal Body Weight, Litter Size, and Litter Sex Ratio.
Pregnant mice were fed a control diet (phytoestrogen fre
freee food pellets) or the control diet
supplemented with 25 mg of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5.
On E18.5,
18.5, mice were sacrificed and fetal body weight (A) and litter size (B)
( were
recorded. Sex ratio of litters were expressed as the percentage of females per total
number of pups in the litter ((C). Data are presented as the mean ± SEM (n = 20).
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3.2 Effects of BPA on Fetal Liver Histology
Standard histological analysis was performed in order to determine whether
prenatal exposure to BPA affects structural maturation of fetal livers at E18.5. Upon
analysis, we found that there were no observable structural differences in BPA exposed
fetal livers (Figure 3-2 B and D) compared to controls (Figure 3-2 A and C).
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Figure 3-2.. Effects of BPA on Fetal Liver Histology. Pregnant mice were fed a control
diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg of
BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice were sacrificed
and fetal
al livers were collected, fixed and subjected to histological analysis.
Representative fetal liver sections from mice fed the control diet (A and C)
C and the
control diet supplemented with 25 mg BPA/kg diet (B and D) are shown (n = 3).
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3.3 Effects of BPA on Albumin Protein Expression
To determine whether prenatal exposure to BPA affected fetal liver maturation,
we first examined albumin expression, a well-known marker of, and the most abundant
protein synthesized by, mature hepatocytes [60,87,88]. We found that levels of albumin
protein were significantly decreased in BPA-exposed female fetal livers when compared
to controls (35% of control; Figure 3-3 A and C). In marked contrast, the abundance of
albumin protein was not altered in the fetal livers of BPA-exposed males (Figure 3-3 B
and D).
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Figure 3-3.. Effects of BPA on albumin protein expression. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg
of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice were
sacrificed andd fetal livers were collected, flash frozen in liquid nitrogen, and stored at 80°C. Levels of albumin protein in female ((A and C) and male (B and D)) fetal livers were
determined by western blot analysis. Data are ppresented as the mean ± SEM (***P <
0.001; n = 4 litters, livers from three pups were pooled per litter).
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3.4 Effects of BPA on Glycogen Synthase Protein Expression
Glycogen storage is an important marker of mature hepatocytes [88,96,97]. Prior
to birth, a rapid accumulation of glycogen in the fetal liver is accompanied by a
corresponding increase in glycogen synthase [93,120]. We next determined changes in
the expression of glycogen synthase. We found that the level of glycogen synthase
protein was significantly decreased in the fetal livers of female BPA-exposed mice when
compared to controls (60% of control; Figure 3-4 A and C). However, there was no
change in the level of glycogen synthase protein in BPA-exposed male fetal livers
(Figure 3-4 B and D).
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Figure 3-4.. Effects of BPA on glycogen synthase protein expression. Pregnant mice
were fed a control diet (phytoestrogen free food pellets) or the control diet supplemented
with 25 mg of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice
were sacrificed and fetal livers were collected, flash frozen in liquid nitrogen, and stored
at -80°C.
80°C. Levels of glycogen synthase (GS) protein in female ((A and C)) and male (B
( and
D)) fetal livers were determined by western blot analysis. Data are presented as the mean
± SEM (**P < 0.01; n = 4 litters, livers from three pups were pooled per litter).
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3.5 Effects of BPA on AFP Protein Expression
To gain further insight into the effects of BPA on fetal liver maturation, we
examined changes in the expression of AFP, a well-known marker of immature
hepatocytes [89,90]. We found that levels of AFP protein were significantly increased in
BPA-exposed female fetal livers when compared to controls (143% of control; Figure 35 A and C). In contrast, AFP protein abundance was not changed in BPA-exposed male
fetal livers (Figure 3-5 B and D).
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Figure 3-5.. Effects of BPA on AFP protein expression. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg
of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice were
sacrificed and fetal livers were collected, flash frozen in liquid nit
nitrogen,
rogen, and stored at 80°C. Levels of AFP protein in female ((A and C) and male (B and D)) fetal livers were
determined by western blot analysis. Data are presented as the mean ± SEM (*P
(* < 0.05; n
= 4 litters, livers from thr
three pups were pooled per litter).
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3.6 Effects of BPA on C/EBP-α Protein Expression
Given that C/EBP-α is a master transcription factor essential for hepatocyte
differentiation [86,121], we sought changes in the expression of this transcription factor
following exposure to BPA. We showed that levels of C/EBP-α protein were decreased
by 50% in BPA-exposed female fetal livers when compared to controls (Figure 3-6 A
and C). By contrast, the level of C/EBP-α protein in BPA-exposed male fetal livers was
not changed (Figure 3-6 B and D).
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Figure 3-6.. Effects of BPA on C/EBP
C/EBP-α protein expression. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg
of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice were
sacrificed and fetal livers were collected, flash frozen in liquid nitrogen, and stored at 80°C. Levels of C/EBP-α
α protein in female (A and C) and male (B and D) fetal livers
were determined by western blot analysis. Data are presented as the mean ± SEM (*P <
0.05; n = 4 litters, livers from three pups were pooled per litter).
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3.7 Effects of BPA on PCNA Protein Expression
Normal organ growth and maturation depends critically on the right balance
between cell proliferation and apoptosis [80]. Thus, we sought to determine if this
balance might be perturbed in BPA-exposed fetal livers. To do so, we first examined the
proliferative status of the BPA-exposed fetal liver by analyzing the expression of PCNA,
a universal marker of cell proliferation. We showed that levels of PCNA protein were upregulated significantly in BPA-exposed female fetal livers when compared to controls
(160% of control; Figure 3-7 A and C). In contrast, the level of PCNA protein was
unchanged in BPA-exposed male fetal livers (Figure 3-7 B and D).
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Figure 3-7.. Effects of BPA on PCNA protein expression. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg
of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice were
sacrificed and fetal livers were collected, flash frozen in liquid nitrogen, and stored at 80°C. Levels of PCNA protein in female ((A and C) and male (B and D)) fetal livers were
determined by western blot analysis. Data ar
are presented as the mean ± SEM (*P
(* < 0.05; n
= 4 litters, livers from three pups were pooled per litter).
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3.8 Effects of BPA on Caspase-3 Protein Expression
We then examined the effect of BPA on the expression of caspase-3, a universal
marker of apoptosis. We found that protein levels of both procaspase-3 (60% of control;
Figure 3-8 A and C) and cleaved caspase-3 (45% of control; Figure 3-8 A and 6E) were
significantly down-regulated in BPA-exposed female fetal livers when compared to
controls. By contrast, no changes in the protein level of either procaspase-3 (Figure 3-8
B and D) or cleaved caspase-3 (Figure 3-8 B and F) were observed in livers of BPAexposed male fetuses.
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Figure 3-8.. Effects of BPA on caspase
caspase-3 protein expression. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg
of BPA/kg food pellets from embryonic day (E) 7.5 to 18.5. On E18.5, mice were
sacrificed and fetal livers were collected, flash frozen in lliquid
iquid nitrogen, and stored at 80°C. Levels of procaspase
procaspase-3 protein and cleaved caspase-3
3 protein in female (A
( and C)
and male (B and D)) fetal livers were determined by western blot analysis. Data are
presented as the mean ± SEM (*
(*P < 0.05, **P < 0.01; n = 4 litters, livers from three
thr pups
were pooled per litter).
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Chapter 4 – Discussion
There is robust evidence that adverse events in early life can permanently alter
organ growth and function, leading to a wide range of diseases later in life, including
cardiovascular, metabolic, neurological, reproductive, and behavioral disorders as well as
cancers [49,51]. Although developmental exposure to BPA has been shown to cause liver
dysfunction and diseases, the effects of BPA on liver development had never been
explored. In the present study, we addressed this important question, and demonstrate
that in utero exposure to environmentally relevant doses of BPA via maternal diet
disrupts female, but not male, fetal liver maturation in the mouse. Thus, our findings
suggest a fetal origin for BPA-induced liver dysfunction and metabolic diseases.

4.1 Dosage
The dosage of BPA used, 25 mg BPA/kg diet (equivalent to 5 mg/kg/day), in the
present study was chosen to mimic BPA exposure at environmentally relevant levels, and
had been shown by us previously not to alter fetal body weight when examined at E18.5
[47]. Further, no changes were apparent in litter size or litter sex ratio. This dosage is one
tenth of the NOAEL of 50 mg/kg/day for rodents, as defined by the US EPA [122]. BPA
exposure was initiated at E7.5, subsequent to successful implantation and just prior to the
onset of liver development, and continued until E18.5, one day before term. Although
maternal blood BPA levels were not measured in the present study, they were estimated
to be 20 ng/ml at the maximum. This estimation was based on a previous study, in which
pregnant mice were fed 5 mg BPA/kg diet for a total of 28.5 days (prior to mating and
throughout pregnancy), and maternal plasma levels of BPA were found to be 4 ng/ml
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[38]. Thus, the estimated maternal circulating levels of BPA in our study are within the
range of 0.5–22.3 ng/ml, which has been reported in pregnant women of the US [56].

4.2 BPA Decreases Albumin Protein Expression in Fetal
Female Livers
In the mouse, liver development begins at E9. At approximately E14, bipotential
hepatoblasts begin to differentiate into either hepatocytes or bile duct epithelial cells [71].
By E16, these two distinct cell types become irreversibly differentiated but continue to
undergo maturation for several weeks after birth [75], at which time they are considered
mature hepatocytes and cholangiocytes, respectively. In adults, hepatocytes are the main
functional units of the liver accounting for nearly 80% of the total liver volume [59,60].
The adult liver in mammals produces a myriad of proteins and enzymes that are crucial
for maintaining homeostasis, the most abundant of which is albumin, constituting more
than half of total plasma proteins [81]. Albumin is first expressed in fetal hepatocytes at
E12, and its expression increases progressively thereafter until it reaches maximal levels
in the adult [71]. Consequently, albumin is considered a hallmark of hepatocyte
maturation [60,87,88]. As a first step in examining the effects of BPA on fetal liver
maturation, we analyzed albumin protein expression. We found that levels of albumin
protein were significantly reduced in BPA-exposed female fetal livers when compared to
controls. In marked contrast, BPA had no effect on albumin protein expression in male
fetal livers, demonstrating that BPA disrupts fetal liver maturation in a sex-specific
manner.
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4.3 BPA Decreases Glycogen Synthase Protein Expression
in Fetal Female Livers
Glycogen accumulation is another key feature of mature hepatocytes, and an
important marker of hepatic maturation [88,96]. During most of gestation, hepatic
glycogen store remains low as the fetus obtains an adequate supply of glucose from the
mother via the placenta [91]. During late gestation, hepatocytes start to accumulate
significant amounts of glycogen in order to prepare for the extrauterine survival at birth
[92]. This surge in glycogen accumulation is accompanied by a corresponding increase in
glycogen synthase [93,120], the rate-limiting enzyme of glycogen synthesis [94,95]. In
the present study, therefore, we examined glycogen synthase protein expression and used
it as a surrogate of glycogen accumulation. We showed that similar to its effects on
albumin, prenatal BPA exposure significantly downregulated fetal liver glycogen
synthase expression in females but not males. This finding further supports our
conclusion that BPA disrupts fetal liver maturation in a sex-specific manner. Although
glycogen content was not measured in the present study, previous studies have found that
changes in fetal glycogen accumulation are directly correlated with alterations in
glycogen synthase expression [96,123]. In addition, one previous study has shown that
the developmental increase in fetal liver glycogen synthase expression is critically
determined by the status of hepatocyte differentiation rather than substrate availability
[120].
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4.4 BPA Increases AFP Protein Expression in Fetal Female
Livers
To provide further insight into the effects of BPA on fetal liver maturation, we then
examined the expression of AFP, a marker of immature fetal hepatocytes [89,90]. AFP is
the predominant fetal plasma protein produced by the fetal liver [85], and is considered
the fetal equivalent of the adult serum albumin. During fetal development, the liver
produces increasing amounts of AFP from E9 up to E15.5, at which time, AFP
production begins to decline as the liver matures, ultimately becoming undetectable in the
adult [86]. Here, we showed that in female livers, prenatal BPA exposure resulted in a
significant increase in AFP protein expression at E18.5. In contrast, AFP protein levels in
BPA-exposed male fetal livers were comparable to those of non-exposed controls. Taken
together, the distinct changes in the expression of all three markers corroborate each
other, and provide powerful evidence that prenatal exposure to BPA severely impairs
fetal hepatic maturation only in females and not males.

4.5 BPA Decreases C/EBP-α Protein Expression in Fetal
Female Livers
C/EBP-α is a master transcription factor essential for hepatocyte maturation, and is
necessary for the activation of several genes associated with differentiated hepatocytes
[121]. As the liver undergoes maturation, C/EBP-α expression increases progressively
until reaching a maximum in the adult [86]. Because of its temporal expression profile
during liver development, C/EBP-α is also considered a marker of mature hepatocytes.
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Consequently, we determined whether prenatal BPA exposure affected the expression of
this key transcription factor in fetal livers. We found that C/EBP-α protein levels were
significantly decreased in BPA-exposed female fetal livers. Similar to the other markers
of hepatic maturation, the level of C/EBP-α protein remained unaltered in BPA-exposed
male fetal livers. The reduced hepatic C/EBP-α expression in BPA-exposed female fetal
livers not only supports our conclusion that BPA disrupts fetal hepatic maturation in a
sex-specific manner, but also suggests that the altered expression of albumin, glycogen
synthase and AFP is likely a result of the decreased C/EBP-α expression.
Indeed, neonatal livers of C/EBP-α knockout mice exhibit properties characteristic
of a dedifferentiated state. In an in vivo study by Wang et al., C/EBP-α knockout mice
displayed normal body weight and gross organ morphology, however they failed to
survive more than one day after birth due to impaired energy homeostasis [107]. In
particular, C/EBP-α knockout mice displayed significantly decreased glycogen stores at
both E18 and 1 hour postpartum. In fact, while control mice produced abundant levels of
hepatic glycogen stores, those void of C/EBP-α exhibited virtually none [107]. These
diminished glycogen stores were accompanied by a 50-70% decrease in glycogen
synthase mRNA levels, which suggests that the lack of hepatic glycogen was a direct
consequence of insufficient glycogen synthase [107]. Thus, although glycogen was not
directly measured in the present study, it is highly likely that hepatic glycogen stores are
reduced as a consequence of significantly decreased glycogen synthase. Conversely,
C/EBP-α knock-in mice demonstrate earlier fetal hepatic glycogen deposition (E15.5) in
comparison to their wild type littermates, with a corresponding increase in glycogen
synthase expression [123].
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Wang et al. also demonstrated C/EBP-α knockout mice display significantly
reduced albumin mRNA at 2 hours after birth, which remained low at both 7 and 32
hours postpartum, suggesting that C/EBP-α regulation is required for the transcriptional
induction of the albumin gene [107]. Because albumin expression was not completely
absent, it is likely that the albumin gene might be fully transactivated by the activity of
C/EBP-α together with some other liver-enriched transcription factor(s) known to bind to
the albumin promoter [107]. This reduced albumin was also recapitulated in another in
vivo C/EBP-α knockout model by Flodby et al. [106], and consistent with results from an
in vitro model of C/EBP-α knock-in hepatocytes where albumin mRNA and protein
levels were increased [104]. In addition, neonatal C/EBP-α knockout mice exhibit
significantly elevated levels of AFP, indicative of a less differentiated state [106].

4.6 BPA Increases Cell Proliferation Marker PCNA in Fetal
Female Livers
A proper balance between cell proliferation and apoptosis is essential for organ
development, including that of the liver [80]. Thus, we also determined whether prenatal
BPA exposure disrupted this balance in the fetal liver. First, we examined the
proliferative status of the fetal liver by analyzing the expression of PCNA, a universal
marker of cell proliferation. One of the main characteristics of a differentiated cell is a
marked decrease in proliferation. As hepatocytes mature during fetal development, their
proliferative activity progressively decreases as they approach term [124]. Hence,
increased expression of proliferative markers is likely indicative of impaired hepatic
differentiation and maturation [96]. In the present study, we found that levels of PCNA
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protein were significantly elevated in BPA-exposed female but not male fetal livers. It is
interesting to note that prenatal BPA exposure has been shown to increase proliferation in
the pituitary gland of female but not male mice at birth [125].
Given that we revealed a significant decrease in C/EBP-α expression in female
fetal livers, it is especially noteworthy that this transcription factor is known to exert
powerful inhibitory effects on cell proliferation. For instance, hepatocyte proliferation is
induced in C/EBP-α knockout mice [106,126], whereas C/EBP-α overexpression results
in significantly reduced proliferative activity [127]. C/EBP-α is also highly expressed in
terminally differentiated tissues and in non-dividing hepatocytes [128]. Furthermore,
during liver regeneration [128–130] and tumorigenesis [104], instances during which
proliferative activity is positively driven, C/EBP-α is significantly downregulated, which
is accompanied by a corresponding re-activation of AFP [123]. Thus, it is tempting to
speculate that the increased PCNA expression, and by inference hepatic proliferation, as
observed in the present study may be a consequence of decreased C/EBP-α.

4.7 BPA Decreases Apoptotic Marker Caspase-3 in Fetal
Female Livers
During normal fetal development, an appropriate level of apoptosis is necessary
for controlling cell population and deleting abnormal or genetically damaged cells
[80,131]. Moreover, organ homeostasis is critically regulated by the balance between cell
gain and cell loss [132]. Given that female fetal livers exhibited aberrant cell proliferation
in response to BPA exposure, we then sought to examine if BPA exerted an effect on
apoptosis. Previous studies have shown that prenatal exposure to BPA decreases
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apoptosis in the fetal mammary gland, leading to delayed lumen formation at E18 in the
mouse [41,42]. With regards to the liver, Xia et al. found that BPA exposure during
pregnancy and lactation resulted in enhanced apoptosis in male offspring at 15 and 21
weeks of age [109], but females were not examined.
Apoptotic cell death is carried out via two major pathways: the extrinsic (death
receptor) pathway, and the intrinsic (mitochondrial) pathway. The two main initiator
caspases associated with each of those pathways are caspase-8 and caspase-9,
respectively [133]. These two pathways converge, and apoptosis is carried out by the
cleavage of the executioner protein caspase-3 [134]. Thus, in the present study, we
analyzed the expression of caspase-3 (a universal apoptotic marker) to determine the
effect of prenatal BPA exposure on apoptosis in fetal livers. Our results showed a
significant decrease in levels of both pro- and cleaved (active) caspase-3 in BPA-exposed
female fetal livers, suggesting that BPA reduced both the expression and activity of
caspase-3. By contrast, neither pro- nor cleaved caspase-3 protein levels were altered in
BPA-exposed male fetal livers.
While decreased albumin, decreased glycogen synthase, increased AFP, and
increased proliferation in BPA-exposed females can be largely attributed to the lack of
C/EBP-α, there is no evidence that this transcription factor directly affects apoptosis in
hepatocytes. In one study, C/EBP-α was found to ameliorate liver fibrosis in mice
through the induction of apoptosis in hepatic stellate cells [134]. However, apoptosis of
hepatocytes generally remained unaltered [134]. In the present study, suppressed
apoptosis in BPA-exposed females could potentially be a direct consequence of the
upregulated cell replication [132], especially given that both of these processes were
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altered strictly in females, and not males. Indeed, results from previous studies have
indicated that cell proliferation and apoptosis are coupled processes, and hence,
suppression of apoptosis may occur as part of a proliferative response [135]. In any case,
decreased apoptotic activity is particularly unfavourable during organogenesis. Especially
in combination with the observed increase in cell proliferation, suppression of apoptosis
could cause hyperplasia, which creates an expanded population of cells from which those
with oncogenic mutations could arise.

4.8 Sex-Specific Effects
The most striking findings of the present study are the sex-specific effects of BPA
on fetal liver maturation. We are not the first to demonstrate that male and female fetal
livers display differential vulnerability in response to an adverse in utero environment.
For example, maternal protein and nutrient restriction [136,137], maternal smoking
[138,139], prenatal caffeine exposure [140], and prenatal cadmium exposure [141] have
been shown to alter fetal hepatic gene expression and DNA methylation in a sexdependent manner. Although the precise molecular mechanisms underlying the sexspecific effects in the present study and those reported previously remain largely
unknown, it is possible that fetal sex steroid hormones may play a role [142]. A likely
contributing factor may also be sex chromosome complement, because chromosomal
differences have been shown to dictate the responses of male and female cells to
environmental stressors even before the production of fetal sex hormones [143,144]. It is
also possible that these sex-specific effects could be mediated indirectly via differential
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effects of BPA on male and female placentas [145]. Obviously, future studies will be
required to determine the precise mechanisms underlying this phenomenon.
Our present findings also suggest females are more vulnerable to BPA-induced
hepatic damage. This contention is consistent with some but not all of the previously
reported sexual dimorphism associated with the BPA-induced adult liver phenotypes,
which appear to be largely dependent on the dose as well as the exposure time and
duration. For instance, although maternal exposure to BPA throughout pregnancy and
lactation has been shown to induce metabolic disorders in both male and female adult
offspring, the effects on females were more profound [112]. In contrast, AlonsoMagdalena et al. found that prenatal exposure to BPA (E9 to E16) disrupted glucose
homeostasis in adult male but not female offspring [111]. In another study, Weinhouse et
al. found that exposure to BPA throughout gestation and lactation led to a dose-dependent
incidence of liver tumors in both male and female adult offspring [110]. Although these
effects were not different between sexes, it is interesting to note that while males are
normally two to four times more likely to develop hepatocellular carcinoma (HCC), this
sexual dimorphism disappeared as a result of perinatal BPA exposure [110]. This BPAinduced increased vulnerability to HCC in adult females is especially interesting in the
context of the present study’s findings for C/EBP-α, given that C/EBP-α knock-in mice
have been shown to exhibit reduced susceptibility to HCC compared to wild-types [123],
and also given its suspected role as a tumor suppressor in other tissues [146].
Developmental exposure to BPA has also been shown to promote aberrant DNA
methylation profiles [115,116] as well as altered gene expression [113] in adult offspring.
However, sex-specific effects are unknown as differences between sexes were never
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compared in these studies. For example, Ma et al. revealed glucokinase promoter
hypermethylation in adult male offspring as a result of early life BPA exposure, but
female offspring were never examined [116]. In another study, Somm et al. showed that
perinatal BPA exposure resulted in the overexpression of several hepatic metabolic genes
in adult female offspring, but gene expression in male livers was not analyzed [113].
Early life exposure to BPA also contributes to the development of hepatic steatosis in
adult male offspring [108,147] but this phenomenon has never been examined in BPAexposed females.

4.9 Conclusions
In the present study, we demonstrate for the first time that prenatal exposure to
environmentally relevant doses of BPA via maternal diet impairs female, but not male,
fetal liver maturation in the mouse. Although the long-term consequences of the present
findings remain to be determined, it is tempting to speculate that the disrupted hepatic
maturation observed in the present study may result in permanent alterations in hepatic
function, ultimately leading to hepatic dysfunction and diseases later in life. In addition,
these findings suggest that females are more vulnerable to BPA-induced hepatic damage.

4.10 Limitations & Future Directions
Although we provide strong evidence that BPA impairs the biochemical
maturation of female fetal livers, the liver also undergoes structural maturation to acquire
a specialized tissue architecture important for supporting its associated functions [148]. In
the present study, no definitive conclusion can be made regarding the effects of prenatal
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BPA exposure on structural maturation of fetal livers. While there were no observable
structural abnormalities in the livers of BPA-exposed fetuses upon standard H&E
staining, this histological analysis was carried out on a small sample size with males and
females pooled together, prior to the realization of a sex-specific effect. Thus, an
impairment in the structural maturation of female fetal livers could potentially be masked
by the strong lack of effect of BPA on the livers of male fetuses. Unfortunately, further
analysis was not possible in the present study since the limited store of fixed tissues was
never genotyped. Future studies should explore this by analyzing structural markers of
maturation [96]. Moreover, one of the most utilized indices for assessing effects of
xenobiotics is organ weight [149]. In the present study, fetal liver weights failed to be
recorded at the time of dissection. However, neonatal livers of C/EBP-α knock-out mice
exhibit a normal liver size [106,150], which leads us to believe that liver weights of BPAexposed fetal females likely remain normal in the present study. Nevertheless, this
question should be addressed in future studies.
Our study employed the use of an in vivo mouse model to demonstrate the effects
of prenatal BPA exposure on fetal liver maturation in the mouse at E18.5, just prior to
term (E19). This time point was chosen since our goal was to determine whether a fetal
origin might exist for BPA-induced hepatic disease and dysfunction. Nevertheless,
hepatocytes continue to undergo functional maturation for several weeks after birth, and
C/EBP-α is also essential for continued postnatal differentiation of hepatocytes. For
example, the rapid depletion of glycogen stores at birth is paralleled by the immediate
onset of hepatic gluconeogenesis [151]. The acquired gluconeogenic capacity of the liver
is supported by the onset of gluconeogenic enzymes, including glucose-6-phosphatase
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(G6Pase) and the rate-limiting enzyme, phosphoenolpyruvate carboxykinase (PEPCK), at
postnatal day (PN) 1 [152–154]. C/EBP-α binds to the promoter regions of these genes
and activates their expression [155,156]. In fact, neonatal C/EBP-α knockout mice
exhibit delayed and reduced PEPCK and G6Pase expression, which is largely responsible
for their severe dysregulation in glucose homeostasis and resultant hypoglycemia
[107,155]. In the present study, given that levels of C/EBP-α are significantly decreased
in BPA-exposed female livers at E18.5, it is likely that these important gluconeogenic
enzymes are also downregulated in the neonatal liver, and that the consequences of
prenatal BPA exposure on hepatocyte maturation extend into the postnatal period. Future
studies are necessary in order to address these questions.
Furthermore, it is unknown as to whether the effects observed in the present study
persist into adulthood. Liver-specific knockout models have revealed that C/EBP-α
continues to play an important role in the adult. Specifically, these studies have
demonstrated that C/EBP-α is necessary for transcription of critical gluconeogenic genes
(glycogen synthase, G6Pase, PEPCK), as well as bilirubin UGT, which is required for the
detoxification of serum bilirubin [157,158]. In addition, adult C/EBP-α knockout mice
have been shown to exhibit glucose intolerance, increased hepatic steatosis, and increased
serum cholesterol levels [158]. Thus, programmed under-expression of hepatic C/EBP-α
could have negative consequences in the adult. Interestingly, a subset of these profiles
have already been established in adult mice subjected to early life BPA exposure. It
would be interesting to understand the extent to which downregulated C/EBP-α in the
fetus contributes to these phenotypes, if at all.
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Lastly, we have yet to elucidate the molecular mechanism underlying the effect of
BPA on female fetal liver maturation. We propose that upon binding to an intracellular
receptor, BPA acts to downregulate C/EBP-α protein expression, which leads to a
downregulation of albumin and glycogen synthase, an upregulation of AFP, as well as
increased PCNA expression (cell proliferation marker) and decreased caspase-3
expression (marker of apoptosis) (Figure 4-1). However, the precise mechanism remains
unclear, and future studies will be necessary in order to address this question.
It is conceivable that prenatal exposure to BPA impairs female fetal liver
maturation through aberrant estrogen signaling. As previously mentioned, BPA acts
mainly via interaction with ER. The predominant isoform in hepatocytes is ERα
[159,160], and studies have shown that hepatic ER concentrations increase in the fetus
during later stages of gestation in parallel with maternal estrogens [161]. In other cell
types that coexpress C/EBP-α and ER, estradiol has been shown to induce C/EBP-α
activation [162]. Additionally, BPA has been shown to act via an ER-mediated pathway
to increase C/EBP-α expression in human adipose stem cells [163].
BPA has also been shown to bind to the GR as both an agonist and an antagonist
[30,31]. Glucocorticoids are important for regulating the expression of many hepatic
genes. Specifically, the GR regulates transcription via DNA binding, as well as through
cross-talk with other transcription factors [164,165]. Studies have shown that during late
gestation, glucocorticoids promote hepatic maturation. For example, glucocorticoids
accelerate the decline of AFP while enhancing albumin expression [166]. In addition,
glucocorticoid have been shown to induce glycogen synthase expression and glycogen
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accumulation [167]. Glucocorticoids have also been shown to induce G1 cell cycle arrest
in a rat hepatoma cell line, which required the induction of C/EBP-α as a mediator [165].
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Figure 4-1. Proposed Mechanism. Upon binding to an intracellular receptor, BPA acts
to downregulate C/EBP-α, which leads to decreased expression of albumin and glycogen
synthase, increased expression of AFP, as well as a perturbed balance between cell
proliferation and apoptosis.
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